Skip to main content

Table 2 Average acute effectiveness, assessed using the Wilcoxon signed rank test, is unchanged following each patient’s longest cluster attack remission (p = 0.2188)

From: Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months

Acute outcomes in patients with remission

Remission patient

Attack frequency (attacks/wk) at baseline

Days of stimulation prior to first remission

Consecutive (longest) remission duration (days)

Calendar months during (longest) remission

% of attacks achieving effective therapy (# effective therapy/total treated)

Before Remission

After Remission

1

45

212

322

Feb -> Nov

0 % (0/203)

0 % (0/1)

2

8

272

215

Dec -> Aug

62 % (18/29)

64 % (32/50)

3

7

63

182

Dec -> Jun

0 % (0/4)

46 % (6/13)

4

35

42

133

Aug -> Dec

33 % (3/9)

7 % (2/30)

5

16

238

280

Jul -> Apr

57 % (12/21)

52 % (12/23)

6

10

21

106

Jul -> Nov

38 % (11/29)

43 % (3/7)

7

20

113

64

Aug -> Oct

21 % (4/19)

56 % (14/25)

8

7

174

63

Mar -> May

47 % (14/30)

100 % (33/33)

9

5

119

63

Oct -> Dec

36 % (4/11)

33 % (1/3)

10

20

84

62

Apr -> Jun

74 % (14/19)

91 % (29/32)

Avg ± SD

17.3 ± 13.3

133.8 ± 86.3

149.0 ± 96.7

-

36.8 ± 31.8 %

49.2 ± 31.8 %

(p = 0.2188)